---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346857"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-08-12T20:10:20+00:00"
generated_at: "2026-08-12T20:11:13.398912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara Q2 net loss $4.8M; FDA meeting backs tab-cel BLA resubmission

## Summary
- Q2 2026 net loss of $4.8M ($0.32/share) vs net income of $2.4M in Q2 2025.
- Total revenues $0.6M vs $17.6M YoY, down $17.0M on deferred revenue acceleration.
- Cash and short-term investments $9.9M at June 30, 2026; operating expenses down 87% YoY.
- Cash runway into mid-2027; productive Type A FDA meeting supports tab-cel BLA resubmission.
- Eligible for $31M milestone on FDA approval plus tiered royalties on EBVALLO sales.

## SEC filing metadata
- accession: 0001193125-26-346857
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-08-12T20:10:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/0001193125-26-346857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346857
- JSON: https://secwatch.observer/filing/0001193125-26-346857.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.